Eintrag weiter verarbeiten
Interleukin‐2 Activation of Haematopoietic Stem Cells
Gespeichert in:
| Zeitschriftentitel: | Acta Medica Austriaca |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , , , , , |
| In: | Acta Medica Austriaca, 29, 2002, 2, S. 61-67 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Wiley
|
| Schlagwörter: |
| author_facet |
Hájek, R. Kořístek, Z. Vinklárková, J. Janovská, E. Klabusay, M. Doubek, M. Dvořáková, D. Bourková, L. Dušek, L. Büchler, T. Adler, J. Adam, Z. Penka, M. Mayer, J. Vorlíček, J. Hájek, R. Kořístek, Z. Vinklárková, J. Janovská, E. Klabusay, M. Doubek, M. Dvořáková, D. Bourková, L. Dušek, L. Büchler, T. Adler, J. Adam, Z. Penka, M. Mayer, J. Vorlíček, J. |
|---|---|
| author |
Hájek, R. Kořístek, Z. Vinklárková, J. Janovská, E. Klabusay, M. Doubek, M. Dvořáková, D. Bourková, L. Dušek, L. Büchler, T. Adler, J. Adam, Z. Penka, M. Mayer, J. Vorlíček, J. |
| spellingShingle |
Hájek, R. Kořístek, Z. Vinklárková, J. Janovská, E. Klabusay, M. Doubek, M. Dvořáková, D. Bourková, L. Dušek, L. Büchler, T. Adler, J. Adam, Z. Penka, M. Mayer, J. Vorlíček, J. Acta Medica Austriaca Interleukin‐2 Activation of Haematopoietic Stem Cells General Medicine |
| author_sort |
hájek, r. |
| spelling |
Hájek, R. Kořístek, Z. Vinklárková, J. Janovská, E. Klabusay, M. Doubek, M. Dvořáková, D. Bourková, L. Dušek, L. Büchler, T. Adler, J. Adam, Z. Penka, M. Mayer, J. Vorlíček, J. 0303-8173 1563-2571 Wiley General Medicine http://dx.doi.org/10.1046/j.1563-2571.2002.02005.x <jats:p><jats:bold>Summary:</jats:bold> <jats:styled-content>Background</jats:styled-content>: Recent findings concerning the role of immunity in the eradication of residual malignant disease after autologous haematopoietic stem cell transplantation have led to extensive studies of T‐cell and natural killer (NK) mediated anti‐tumour effects. Interleukin 2 (IL‐2) activation of autologous bone marrow (BM) or peripheral blood stem cells (PBSC) before transplantation is one of the methods of adoptive cell therapy. <jats:styled-content>Methods</jats:styled-content>: Autologous BM of patients with chronic myelogenous leukaemia (<jats:italic>n</jats:italic> = 11) and PBSC of patients with multiple myeloma (<jats:italic>n</jats:italic> = 14) were activated by IL‐2 in laboratory conditions with the aim of evaluating the feasibility of this method, the activation of T and NK cells, recovery of active progenitor cells, microbial contamination, and reduction of malignant cell content. <jats:styled-content>Results</jats:styled-content>: Samples of BM (mean 2.6 × 10<jats:sup>6</jats:sup> cells) and PBSC (mean 10.3 × 10<jats:sup>6</jats:sup> cells) were cultured in complete culture medium with IL‐2 (6000 UI/ml) for 24 h. The recovery of CD34+ cells and CFU‐GM was 82.5 % and 51.5 %, respectively, for BM, and 85 % and 86 %, respectively, for PBSC (mean values). No purging effect was detected by flow cytometry and a small decline in malignant cell contamination was observed by quantitative PCR in BM samples. No microbial contamination occurred during the sample processing. <jats:styled-content>Conclusions</jats:styled-content>: The described <jats:italic>in vitro</jats:italic> activation of BM and peripheral blood stem cells using IL‐2 was evaluated as a safe and reliable method suitable for clinical application.</jats:p> Interleukin‐2 Activation of Haematopoietic Stem Cells Acta Medica Austriaca |
| doi_str_mv |
10.1046/j.1563-2571.2002.02005.x |
| facet_avail |
Online |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA0Ni9qLjE1NjMtMjU3MS4yMDAyLjAyMDA1Lng |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA0Ni9qLjE1NjMtMjU3MS4yMDAyLjAyMDA1Lng |
| institution |
DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-14 DE-Ch1 |
| imprint |
Wiley, 2002 |
| imprint_str_mv |
Wiley, 2002 |
| issn |
0303-8173 1563-2571 |
| issn_str_mv |
0303-8173 1563-2571 |
| language |
English |
| mega_collection |
Wiley (CrossRef) |
| match_str |
hajek2002interleukin2activationofhaematopoieticstemcells |
| publishDateSort |
2002 |
| publisher |
Wiley |
| recordtype |
ai |
| record_format |
ai |
| series |
Acta Medica Austriaca |
| source_id |
49 |
| title |
Interleukin‐2 Activation of Haematopoietic Stem Cells |
| title_unstemmed |
Interleukin‐2 Activation of Haematopoietic Stem Cells |
| title_full |
Interleukin‐2 Activation of Haematopoietic Stem Cells |
| title_fullStr |
Interleukin‐2 Activation of Haematopoietic Stem Cells |
| title_full_unstemmed |
Interleukin‐2 Activation of Haematopoietic Stem Cells |
| title_short |
Interleukin‐2 Activation of Haematopoietic Stem Cells |
| title_sort |
interleukin‐2 activation of haematopoietic stem cells |
| topic |
General Medicine |
| url |
http://dx.doi.org/10.1046/j.1563-2571.2002.02005.x |
| publishDate |
2002 |
| physical |
61-67 |
| description |
<jats:p><jats:bold>Summary:</jats:bold> <jats:styled-content>Background</jats:styled-content>: Recent findings concerning the role of immunity in the eradication of residual malignant disease after autologous haematopoietic stem cell transplantation have led to extensive studies of T‐cell and natural killer (NK) mediated anti‐tumour effects. Interleukin 2 (IL‐2) activation of autologous bone marrow (BM) or peripheral blood stem cells (PBSC) before transplantation is one of the methods of adoptive cell therapy. <jats:styled-content>Methods</jats:styled-content>: Autologous BM of patients with chronic myelogenous leukaemia (<jats:italic>n</jats:italic> = 11) and PBSC of patients with multiple myeloma (<jats:italic>n</jats:italic> = 14) were activated by IL‐2 in laboratory conditions with the aim of evaluating the feasibility of this method, the activation of T and NK cells, recovery of active progenitor cells, microbial contamination, and reduction of malignant cell content. <jats:styled-content>Results</jats:styled-content>: Samples of BM (mean 2.6 × 10<jats:sup>6</jats:sup> cells) and PBSC (mean 10.3 × 10<jats:sup>6</jats:sup> cells) were cultured in complete culture medium with IL‐2 (6000 UI/ml) for 24 h. The recovery of CD34+ cells and CFU‐GM was 82.5 % and 51.5 %, respectively, for BM, and 85 % and 86 %, respectively, for PBSC (mean values). No purging effect was detected by flow cytometry and a small decline in malignant cell contamination was observed by quantitative PCR in BM samples. No microbial contamination occurred during the sample processing. <jats:styled-content>Conclusions</jats:styled-content>: The described <jats:italic>in vitro</jats:italic> activation of BM and peripheral blood stem cells using IL‐2 was evaluated as a safe and reliable method suitable for clinical application.</jats:p> |
| container_issue |
2 |
| container_start_page |
61 |
| container_title |
Acta Medica Austriaca |
| container_volume |
29 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792336291642212357 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:58:07.066Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Interleukin%E2%80%902+Activation+of+Haematopoietic+Stem+Cells&rft.date=2002-05-01&genre=article&issn=1563-2571&volume=29&issue=2&spage=61&epage=67&pages=61-67&jtitle=Acta+Medica+Austriaca&atitle=Interleukin%E2%80%902+Activation+of+Haematopoietic+Stem+Cells&aulast=Vorl%C3%AD%C4%8Dek&aufirst=J.&rft_id=info%3Adoi%2F10.1046%2Fj.1563-2571.2002.02005.x&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792336291642212357 |
| author | Hájek, R., Kořístek, Z., Vinklárková, J., Janovská, E., Klabusay, M., Doubek, M., Dvořáková, D., Bourková, L., Dušek, L., Büchler, T., Adler, J., Adam, Z., Penka, M., Mayer, J., Vorlíček, J. |
| author_facet | Hájek, R., Kořístek, Z., Vinklárková, J., Janovská, E., Klabusay, M., Doubek, M., Dvořáková, D., Bourková, L., Dušek, L., Büchler, T., Adler, J., Adam, Z., Penka, M., Mayer, J., Vorlíček, J., Hájek, R., Kořístek, Z., Vinklárková, J., Janovská, E., Klabusay, M., Doubek, M., Dvořáková, D., Bourková, L., Dušek, L., Büchler, T., Adler, J., Adam, Z., Penka, M., Mayer, J., Vorlíček, J. |
| author_sort | hájek, r. |
| container_issue | 2 |
| container_start_page | 61 |
| container_title | Acta Medica Austriaca |
| container_volume | 29 |
| description | <jats:p><jats:bold>Summary:</jats:bold> <jats:styled-content>Background</jats:styled-content>: Recent findings concerning the role of immunity in the eradication of residual malignant disease after autologous haematopoietic stem cell transplantation have led to extensive studies of T‐cell and natural killer (NK) mediated anti‐tumour effects. Interleukin 2 (IL‐2) activation of autologous bone marrow (BM) or peripheral blood stem cells (PBSC) before transplantation is one of the methods of adoptive cell therapy. <jats:styled-content>Methods</jats:styled-content>: Autologous BM of patients with chronic myelogenous leukaemia (<jats:italic>n</jats:italic> = 11) and PBSC of patients with multiple myeloma (<jats:italic>n</jats:italic> = 14) were activated by IL‐2 in laboratory conditions with the aim of evaluating the feasibility of this method, the activation of T and NK cells, recovery of active progenitor cells, microbial contamination, and reduction of malignant cell content. <jats:styled-content>Results</jats:styled-content>: Samples of BM (mean 2.6 × 10<jats:sup>6</jats:sup> cells) and PBSC (mean 10.3 × 10<jats:sup>6</jats:sup> cells) were cultured in complete culture medium with IL‐2 (6000 UI/ml) for 24 h. The recovery of CD34+ cells and CFU‐GM was 82.5 % and 51.5 %, respectively, for BM, and 85 % and 86 %, respectively, for PBSC (mean values). No purging effect was detected by flow cytometry and a small decline in malignant cell contamination was observed by quantitative PCR in BM samples. No microbial contamination occurred during the sample processing. <jats:styled-content>Conclusions</jats:styled-content>: The described <jats:italic>in vitro</jats:italic> activation of BM and peripheral blood stem cells using IL‐2 was evaluated as a safe and reliable method suitable for clinical application.</jats:p> |
| doi_str_mv | 10.1046/j.1563-2571.2002.02005.x |
| facet_avail | Online |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA0Ni9qLjE1NjMtMjU3MS4yMDAyLjAyMDA1Lng |
| imprint | Wiley, 2002 |
| imprint_str_mv | Wiley, 2002 |
| institution | DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-Ch1 |
| issn | 0303-8173, 1563-2571 |
| issn_str_mv | 0303-8173, 1563-2571 |
| language | English |
| last_indexed | 2024-03-01T14:58:07.066Z |
| match_str | hajek2002interleukin2activationofhaematopoieticstemcells |
| mega_collection | Wiley (CrossRef) |
| physical | 61-67 |
| publishDate | 2002 |
| publishDateSort | 2002 |
| publisher | Wiley |
| record_format | ai |
| recordtype | ai |
| series | Acta Medica Austriaca |
| source_id | 49 |
| spelling | Hájek, R. Kořístek, Z. Vinklárková, J. Janovská, E. Klabusay, M. Doubek, M. Dvořáková, D. Bourková, L. Dušek, L. Büchler, T. Adler, J. Adam, Z. Penka, M. Mayer, J. Vorlíček, J. 0303-8173 1563-2571 Wiley General Medicine http://dx.doi.org/10.1046/j.1563-2571.2002.02005.x <jats:p><jats:bold>Summary:</jats:bold> <jats:styled-content>Background</jats:styled-content>: Recent findings concerning the role of immunity in the eradication of residual malignant disease after autologous haematopoietic stem cell transplantation have led to extensive studies of T‐cell and natural killer (NK) mediated anti‐tumour effects. Interleukin 2 (IL‐2) activation of autologous bone marrow (BM) or peripheral blood stem cells (PBSC) before transplantation is one of the methods of adoptive cell therapy. <jats:styled-content>Methods</jats:styled-content>: Autologous BM of patients with chronic myelogenous leukaemia (<jats:italic>n</jats:italic> = 11) and PBSC of patients with multiple myeloma (<jats:italic>n</jats:italic> = 14) were activated by IL‐2 in laboratory conditions with the aim of evaluating the feasibility of this method, the activation of T and NK cells, recovery of active progenitor cells, microbial contamination, and reduction of malignant cell content. <jats:styled-content>Results</jats:styled-content>: Samples of BM (mean 2.6 × 10<jats:sup>6</jats:sup> cells) and PBSC (mean 10.3 × 10<jats:sup>6</jats:sup> cells) were cultured in complete culture medium with IL‐2 (6000 UI/ml) for 24 h. The recovery of CD34+ cells and CFU‐GM was 82.5 % and 51.5 %, respectively, for BM, and 85 % and 86 %, respectively, for PBSC (mean values). No purging effect was detected by flow cytometry and a small decline in malignant cell contamination was observed by quantitative PCR in BM samples. No microbial contamination occurred during the sample processing. <jats:styled-content>Conclusions</jats:styled-content>: The described <jats:italic>in vitro</jats:italic> activation of BM and peripheral blood stem cells using IL‐2 was evaluated as a safe and reliable method suitable for clinical application.</jats:p> Interleukin‐2 Activation of Haematopoietic Stem Cells Acta Medica Austriaca |
| spellingShingle | Hájek, R., Kořístek, Z., Vinklárková, J., Janovská, E., Klabusay, M., Doubek, M., Dvořáková, D., Bourková, L., Dušek, L., Büchler, T., Adler, J., Adam, Z., Penka, M., Mayer, J., Vorlíček, J., Acta Medica Austriaca, Interleukin‐2 Activation of Haematopoietic Stem Cells, General Medicine |
| title | Interleukin‐2 Activation of Haematopoietic Stem Cells |
| title_full | Interleukin‐2 Activation of Haematopoietic Stem Cells |
| title_fullStr | Interleukin‐2 Activation of Haematopoietic Stem Cells |
| title_full_unstemmed | Interleukin‐2 Activation of Haematopoietic Stem Cells |
| title_short | Interleukin‐2 Activation of Haematopoietic Stem Cells |
| title_sort | interleukin‐2 activation of haematopoietic stem cells |
| title_unstemmed | Interleukin‐2 Activation of Haematopoietic Stem Cells |
| topic | General Medicine |
| url | http://dx.doi.org/10.1046/j.1563-2571.2002.02005.x |